c‑met is overexpressed in type I ovarian cancer: Results of an investigative analysis in a cohort of consecutive ovarian cancer patients

Battista,Marco  Johannes; Schmidt,Marcus; Jakobi,Sina; Cotarelo,Cristina; Almstedt,Katrin; Heimes,Anne‑Sophie; Makris,Georgios‑Marios; Weyer,Veronika; Lebrecht,Antje; Hoffmann,Gerald; Eichbaum,Michael

doi:10.3892/ol.2016.4895

c‑met is overexpressed in type I ovarian cancer: Results of an investigative analysis in a cohort of consecutive ovarian cancer patients

Authors:
- Marco Johannes Battista
- Marcus Schmidt
- Sina Jakobi
- Cristina Cotarelo
- Katrin Almstedt
- Anne‑Sophie Heimes
- Georgios‑Marios Makris
- Veronika Weyer
- Antje Lebrecht
- Gerald Hoffmann
- Michael Eichbaum
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, University Medical Center Mainz, Mainz D‑55131, Germany, Department of Pathology, University Medical Center Mainz, Mainz D‑55131, Germany, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Mainz D‑55131, Germany, Department of Gynecology and Obstetrics, Marienkrankenhaus Frankfurt, Frankfurt D‑60318, Germany
Published online on: July 21, 2016 https://doi.org/10.3892/ol.2016.4895
Pages: 2001-2007

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tyrosine kinase c‑met alters signaling cascades such as the BRAF-MAPK and PI3K-PKB pathways. These alterations are involved in the carcinogenesis of type I but not type II ovarian cancer (OC). Therefore, the present study investigated the patterns of c‑met expression in a cohort of consecutive patients with OC. c‑met expression was determined by immunohistochemical analysis. Differences in c‑met overexpression among subgroups of established clinicopathological features, including age, histological subtype, tumor stage, histological grading, post‑operative tumor burden and completeness of chemotherapy, were determined by χ2 test. Cox regression analyses were performed to determine the prognostic effect of c‑met. Survival rates were estimated using the Kaplan‑Meier method. A total of 106 patients were enrolled into the study. c‑met was overexpressed in 20.8% of the entire cohort; 35.7% of patients with type I OC and 8.6% of patients with type II OC showed overexpression (P=0.001). However, c‑met overexpression was not associated with any other established clinicopathological features (all P‑values >0.05). Univariate Cox regression analysis showed that overexpression of c‑met was associated neither with progression‑free survival (PFS) nor with disease‑specific survival (DSS) (P=0.835 and P=0.414, respectively). Kaplan‑Meier plots also failed to demonstrate an effect of c‑met on the 5‑year PFS and DSS rates (P=0.938 and P=0.412, respectively). These findings support the hypotheses that the overexpression of c‑met is associated with type I but not type II OC, and that overexpression of c‑met does not affect the prognosis of OC.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer Statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Piek JM, Kenemans P and Verheijen RH: Intraperitoneal serous adenocarcinoma: A critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol. 191:718–732. 2004. View Article : Google Scholar : PubMed/NCBI
3	Levanon K, Crum C and Drapkin R: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 26:5284–5293. 2008. View Article : Google Scholar : PubMed/NCBI
4	Kurman RJ: Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 24(Suppl 10): x16–x21. 2013. View Article : Google Scholar : PubMed/NCBI
5	Landen CN Jr, Birrer MJ and Sood AK: Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 26:995–1005. 2008. View Article : Google Scholar : PubMed/NCBI
6	Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, et al: Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 221:49–56. 2010. View Article : Google Scholar : PubMed/NCBI
7	Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G: Targeting MET in cancer: Rationale and progress. Nat Rev Cancer. 12:89–103. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ma PC, Tretiakova MS, Mackinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, et al: Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 47:1025–1037. 2008. View Article : Google Scholar : PubMed/NCBI
9	Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 4:915–925. 2003. View Article : Google Scholar : PubMed/NCBI
10	Lai AZ, Abella JV and Park M: Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 19:542–551. 2009. View Article : Google Scholar : PubMed/NCBI
11	Trusolino L, Bertotti A and Comoglio PM: MET signalling: Principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 11:834–848. 2010. View Article : Google Scholar : PubMed/NCBI
12	Buckanovich R, Berger R, Sella A, Sikic B, Shen X, Ramies D, Smith DC and Vergote IB: Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 29(suppl): abstract 5008. 2011.
13	Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S and Matsubara O: Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: Their roles in tumor progression and prognostication of the patient. Mod Pathol. 24:1146–1155. 2011. View Article : Google Scholar : PubMed/NCBI
14	Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, et al: c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 67:1670–1679. 2007. View Article : Google Scholar : PubMed/NCBI
15	Goode EL, Chenevix-Trench G, Hartmann LC, Fridley BL, Kalli KR, Vierkant RA, Larson MC, White KL, Keeney GL, Oberg TN, et al: Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 20:1638–1648. 2011. View Article : Google Scholar : PubMed/NCBI
16	Battista MJ, Mantai N, Sicking I, Cotarelo C, Weyer V, Lebrecht A, Solbach C and Schmidt M: Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: Results of an explorative, retrospective study. Oncol Rep. 31:2213–2219. 2014.PubMed/NCBI
17	Battista MJ, Cotarelo C, Jakobi S, Steetskamp J, Makris G, Sicking I, Weyer V and Schmidt M: Overexpression of epithelial cell adhesion molecule protein is associated with favorable prognosis in an unselected cohort of ovarian cancer patients. J Cancer Res Clin Oncol. 140:1097–1102. 2014. View Article : Google Scholar : PubMed/NCBI
18	Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM and Silva EG: Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 28:496–504. 2004. View Article : Google Scholar : PubMed/NCBI